BRPI0811581A2 - Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos - Google Patents

Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos

Info

Publication number
BRPI0811581A2
BRPI0811581A2 BRPI0811581-8A2A BRPI0811581A BRPI0811581A2 BR PI0811581 A2 BRPI0811581 A2 BR PI0811581A2 BR PI0811581 A BRPI0811581 A BR PI0811581A BR PI0811581 A2 BRPI0811581 A2 BR PI0811581A2
Authority
BR
Brazil
Prior art keywords
gsc
stimulators
activities
combinations
treatment
Prior art date
Application number
BRPI0811581-8A2A
Other languages
English (en)
Inventor
Peter Sandner
Hanna Tinel
Johannes-Peter Stasch
Dieter Neuser
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0811581A2 publication Critical patent/BRPI0811581A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0811581-8A2A 2007-05-12 2008-04-29 Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos BRPI0811581A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07009557 2007-05-12
PCT/EP2008/003450 WO2008138483A1 (en) 2007-05-12 2008-04-29 sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS

Publications (1)

Publication Number Publication Date
BRPI0811581A2 true BRPI0811581A2 (pt) 2014-12-09

Family

ID=39624195

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811581-8A2A BRPI0811581A2 (pt) 2007-05-12 2008-04-29 Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos

Country Status (9)

Country Link
US (1) US20100210643A1 (pt)
EP (1) EP2144605A1 (pt)
AU (1) AU2008250643A1 (pt)
BR (1) BRPI0811581A2 (pt)
CA (1) CA2686906A1 (pt)
IL (1) IL201509A0 (pt)
MX (1) MX2009011387A (pt)
RU (1) RU2009145935A (pt)
WO (1) WO2008138483A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
US20120022028A1 (en) * 2009-01-17 2012-01-26 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
US9260424B2 (en) 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
BR112012019666A2 (pt) * 2010-02-05 2017-06-20 Bayer Ip Gmbh estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística
WO2011095553A1 (en) * 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
CA2803688A1 (en) * 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
MX338887B (es) 2012-09-07 2016-05-04 Boehringer Ingelheim Int Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2015011086A1 (en) 2013-07-25 2015-01-29 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
JP2016540017A (ja) * 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
AU2015292833B2 (en) 2014-07-22 2019-11-28 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
KR20250088783A (ko) 2022-11-04 2025-06-17 베링거 인겔하임 인터내셔날 게엠베하 전신 경화증을 치료하기 위한 가용성 구아닐레이트 사이클라제 활성제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20050059660A1 (en) * 2003-08-01 2005-03-17 Pharmacia & Upjohn Company Novel combination
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
WO2006126081A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders

Also Published As

Publication number Publication date
CA2686906A1 (en) 2008-11-20
US20100210643A1 (en) 2010-08-19
EP2144605A1 (en) 2010-01-20
IL201509A0 (en) 2010-05-31
RU2009145935A (ru) 2011-06-20
WO2008138483A1 (en) 2008-11-20
MX2009011387A (es) 2009-11-09
AU2008250643A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
LTC2444424I2 (lt) Pagerintos TM nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
IL201509A0 (en) sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0919195A2 (pt) metodos e aparelhos para o tratamento de transtornos do ouvido, nariz e garganta
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
IL201792A (en) Polyvalent polypeptides, anti-rank-l-directed substances for the treatment of irregularities and bone diseases
CU20080044A7 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
BRPI0810561A2 (pt) métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
WO2008086025A3 (en) Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
BRPI1014994A2 (pt) 2,4-diamino pirimidinas para o tratamento de doenças caracterizadas por proliferação excessiva ou anormal de células
ZA200901523B (en) Use of extracts for the treatment of viral disorders
DK2350093T3 (da) Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.